Comparison of Low-Dose Higher-Relaxivity and Standard-Dose Lower-Relaxivity Contrast Media for Delayed-Enhancement...

Area of Science:

• Cardiovascular Imaging
• Radiology
• Medical Contrast Agents

Background:

• Gadolinium-based MRI contrast agents are crucial for visualizing myocardial tissue.
• Gadobenate dimeglumine exhibits higher relaxivity than gadopentetate dimeglumine.
• Optimizing contrast agent dosage is essential for diagnostic efficacy and safety.

Purpose of the Study:

• To evaluate if a reduced dose of gadobenate dimeglumine (0.1 mmol/kg) yields comparable delayed-enhancement MRI results to a standard dose of gadopentetate dimeglumine (0.2 mmol/kg).
• To assess the diagnostic equivalence of lower-dose gadobenate dimeglumine in patients with myocardial infarction.

Main Methods:

• Blinded randomized crossover study involving 20 patients with myocardial infarction.
• Two delayed-enhancement MRI examinations per patient: one with 0.1 mmol/kg gadobenate dimeglumine, one with 0.2 mmol/kg gadopentetate dimeglumine.
• Quantification of lesion enhancement using relative enhancement ratio (RER) at 5, 10, and 20 minutes post-administration.

Main Results:

• Both contrast agents demonstrated high signal intensity in damaged myocardium (RER > 4).
• Blood RER declined over time for both agents, with a larger reduction observed for gadobenate dimeglumine between 5-10 and 10-20 minutes.
• Similar volumes of enhancement were achieved with 0.1 mmol/kg gadobenate dimeglumine and 0.2 mmol/kg gadopentetate dimeglumine (p = 0.98).

Conclusions:

• Delayed-enhancement MRI using 0.1 mmol/kg gadobenate dimeglumine is qualitatively and quantitatively comparable to 0.2 mmol/kg gadopentetate dimeglumine.
• The study supports the potential for dose reduction of gadobenate dimeglumine in myocardial delayed-enhancement imaging.
• These findings may lead to more efficient and potentially safer contrast agent utilization in cardiac MRI.